SEPN

Over the past six months, Septerna established an at-the-market offering program for up to $150.0 million in stock in March 2026 and announced preclinical characterization of SEP-479 in May 2026. Insider selling included Chief People Officer Samira Shaikhly selling 11,798 shares in May 2026 and COO Elizabeth Bhatt selling 25,000 shares in August 2026, alongside 15,000 shares exercised and sold in June 2026. In July 2026, the company delivered its first development candidate to Novo Nordisk. Septerna reported its second-quarter 2026 financial results in August, with $26.7 million revenue and a $21.7 million net loss for the six months, leading to a 22.87% stock price increase. Rajiv Patni, M.D., was appointed Chief Medical Officer in August 2026, and an inducement grant was announced in September 2026. In October 2026, Septerna initiated a Phase 1 trial for SEP-479. Analyst sentiment has been largely positive, with several firms reiterating 'Buy' or 'Overweight' ratings and increasing price targets, contributing to positive stock movements in early October 2026, and the stock experienced a significant increase of 169.68% from September 2025 to September 2026.